ART gains European clearance for SoftScan device

7 March 2007

Montreal, Canada. ART Advanced Research Technologies Inc. (TSX: ARA), a Canadian producer of optical molecular imaging products, has received the CE certificate for its SoftScan optical breast imaging device, allowing it to be sold throughout the European market.

Obtaining the CE marking enables ART to sell its SoftScan device in all 25 member states of the European Union (EU), as well as in Norway, Iceland, Liechtenstein and Turkey, without having to undergo country specific certifications.

SoftScan is a non-invasive and painless optical imaging technology, which enables the characterization of breast tumours by clinicians as benign or malignant, without exposing the patients to ionizing radiation.

“Obtaining the CE marking represents an important commercial milestone for ART and opens up an important market for our SoftScan device,” said Sébastien Gignac, President and CEO of ART. “We are now one critical step closer to commercialization of SoftScan in Europe.”

Joseph Kozikowski, M.D., ART’s Chief Medical Officer, added: "SoftScan has been received with great interest in Europe, especially in the area of treatment monitoring. I expect this CE marking to help doctors and hospitals across Europe to improve patient care with SoftScan breast imaging."

To top